FY2029 Earnings Estimate for PRCT Issued By Leerink Partnrs

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of PROCEPT BioRobotics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky forecasts that the company will earn $0.48 per share for the year. The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%.

Several other analysts have also recently commented on the company. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. Morgan Stanley reduced their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company reissued an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Truist Financial reaffirmed a "buy" rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $94.29.

Remove Ads

PROCEPT BioRobotics Price Performance

PRCT traded down $3.74 on Thursday, reaching $60.60. The stock had a trading volume of 824,165 shares, compared to its average volume of 940,563. The firm has a 50-day moving average of $74.60 and a 200-day moving average of $80.06. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of -31.08 and a beta of 1.03. PROCEPT BioRobotics has a fifty-two week low of $45.56 and a fifty-two week high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning lifted its holdings in PROCEPT BioRobotics by 88.9% in the 3rd quarter. Creative Planning now owns 9,948 shares of the company's stock worth $797,000 after purchasing an additional 4,681 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in PROCEPT BioRobotics by 12,919.5% during the 3rd quarter. International Assets Investment Management LLC now owns 52,078 shares of the company's stock valued at $4,172,000 after acquiring an additional 51,678 shares during the period. Nisa Investment Advisors LLC lifted its holdings in PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock valued at $89,000 after buying an additional 713 shares in the last quarter. Oak Ridge Investments LLC purchased a new stake in shares of PROCEPT BioRobotics in the third quarter valued at approximately $1,942,000. Finally, Americana Partners LLC purchased a new stake in PROCEPT BioRobotics in the third quarter worth about $1,494,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Reza Zadno sold 26,423 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares in the company, valued at $14,851,521.64. The trade was a 14.75 % decrease in their position. The disclosure for this sale can be found here. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).